![]() |
Company type | Public |
---|---|
Nasdaq:
CTSO Russell 2000 Component | |
Industry | Critical care |
Headquarters | , US |
Products | CytoSorb |
Revenue | US$ 41.0 Mio. (2020) [1] |
Number of employees | 160 |
Website |
cytosorbents |
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. [2] [3] [4]
CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011 [5]) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. [6] [7]
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns ( Toraymyxin), which failed to show significance in a clinical trial for sepsis. [8] The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. [9] Clinicaltrials.gov is giving an overview over running research projects. [10]
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. [11] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma. [12] [13]